Trial reportBMC complementary and alternative medicine2014
Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial.
Trial report in BMC complementary and alternative medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01909037 (Exploratory Non Comparative Study to Evaluate the Efficacy of Highly Bioavailable Curcumin), which is not on this map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploratory Non Comparative Study to Evaluate the Efficacy of Highly Bioavailable Curcumin (Flexofytol) in Patients With Knee Osteoarthritis
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Polyphenols for improvement of inflammation and symptoms in rheumatic diseases: systematic review.Sao Paulo medical journal = Revista paulista de medicinaPooled it
- Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study.Arthritis research & therapy · 2019Trial
- Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study.BMC complementary and alternative medicine · 2018Trial
- Isothiocyanates are detected in human synovial fluid following broccoli consumption and can affect the tissues of the knee joint.Scientific reports · 2017Trial
- Reduction of the Serum Levels of a Specific Biomarker of Cartilage Degradation (Coll2-1) by Hyaluronic Acid (KARTILAGE® CROSS) Compared to Placebo in Painful Knee Osteoarthritis Patients: the EPIKART Study, a Pilot Prospective Comparative Randomized Double Blind Trial.BMC musculoskeletal disorders · 2017Trial
- REJENERAInflammopharmacology · 2026Article
- Curcumin in Arthritis: Molecular Mechanisms, Preclinical Evidence, and Clinical Applications.International journal of molecular sciences · 2026Review
- Pharmacological Insights and Technological Innovations inPharmaceuticals (Basel, Switzerland) · 2026Review
- Plant-derived extracellular vesicles in skin and bone tissue engineering: current status, challenges, and future perspectives.Frontiers in bioengineering and biotechnology · 2026Review
- Current progress of plant-derived exosome-like nanovesicles on the regulation of osteoporosis and osteoarthritis.Annals of medicine · 2025Review
- Natural products in the treatment of osteoarthritis: Current status and prospects.Journal of orthopaedic translation · 2025Review
- Pentoxifylline in Dogs With Osteoarthritis: Comparative Treatment and Efficacy Analysis With Meloxicam.Veterinary medicine and science · 2025Article
- Cartilage Regeneration Potential of Platelet-Rich Plasma versus Plasma Rich in Growth Factors in Knee Osteoarthritis Based on Serum Biomarker of Cartilage Degradation, Coll2-1: A Triple-Blind Randomized Study.Journal of orthopaedic case reports · 2025Article
- Osteoarthritis: Insights into Diagnosis, Pathophysiology, Therapeutic Avenues, and the Potential of Natural Extracts.Current issues in molecular biology · 2024Review
- Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials.ACS pharmacology & translational science · 2023Review
- Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?ACS omega · 2023Review
- Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials.International journal of molecular sciences · 2023Article
- Natural Compounds: Potential Therapeutics for the Inhibition of Cartilage Matrix Degradation in Osteoarthritis.Life (Basel, Switzerland) · 2022Review
- Clinical monitoring in osteoarthritis: Biomarkers.Osteoarthritis and cartilage · 2022Article
- Reconnoitering the Therapeutic Role of Curcumin in Disease Prevention and Treatment: Lessons Learnt and Future Directions.Metabolites · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe management of osteoarthritis (OA) remains a challenge. There is a need not only for safe and efficient treatments but also for accurate and reliable biomarkers that would help diagnosis and monitoring both disease activity and treatment efficacy. Curcumin is basically a spice that is known for its anti-inflammatory properties. In vitro studies suggest that curcumin could be beneficial for cartilage in OA. The aim of this exploratory, non-controlled clinical trial was to evaluate the effects of bio-optimized curcumin in knee OA patients on the serum levels of specific biomarkers of OA and on the evaluation of pain.
methodsTwenty two patients with knee OA were asked to take 2x3 caps/day of bio-optimized curcumin (Flexofytol®) for 3 months. They were monitored after 7, 14, 28 and 84 days of treatment. Pain over the last 24 hours and global assessment of disease activity by the patient were evaluated using a visual analog scale (100 mm). The serum levels of Coll-2-1, Coll-2-1NO2, Fib3-1, Fib3-2, CRP, CTX-II and MPO were determined before and after 14 and 84 days of treatment.
resultsThe treatment with curcumin was globally well tolerated. It significantly reduced the serum level of Coll2-1 (p<0.002) and tended to decrease CRP. No other significant difference was observed with the other biomarkers. In addition, curcumin significantly reduced the global assessment of disease activity by the patient.
conclusionThis study highlighted the potential effect of curcumin in knee OA patient. This effect was reflected by the variation of a cartilage specific biomarker, Coll2-1 that was rapidly affected by the treatment. These results are encouraging for the qualification of Coll2-1 as a biomarker for the evaluation of curcumin in OA treatment.
trial registrationNCT01909037 at clinicaltrials.gov.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.